PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way

PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way

Background Various tumors are insensitive to immune checkpoint blockade (ICB) therapy. Toll-like receptors (TLRs) establish the link between innate and adaptive immunity, which can assist T-cell activation and serve as promising targets for combination to enhance ICB therapy. Here, we aimed to impro...

Full description

Saved in:
Bibliographic Details
Main Authors: Wei Huang, Ji Zhou, Jia Li, Yakun Wan, Chao Hu, Meng Liu, Pan Xu, Feng Tang, Jianhua Sun, Xiaolu Yu, Yiru Long, Binfan Chen, Yongliang Tong, Mengwen Shan, Xiaomin Jia, Henglei Lu, Runqiu Chen, Jin Ren, Guangyi Jin, Likun Gong
Format: Article
Language:English
Published: BMJ Publishing Group 2022-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/10/e004590.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/10/10/e004590.full

Similar Items